Safety Alerts Issued by Regulatory Authorities: Usefulness of Meta-Analysis in Predicting

Safety alerts issued by regulatory authorities: usefulness of meta-analysis in predicting earlier risks

Carlos Alves1,2,3, Francisco Batel Marques1,2, Ana Filipa Macedo3

1. Portuguese Central Regional Pharmacovigilance Unit (UFC), Centre for Health Technology Assessment and Drug Research, AIBILI, Coimbra, Portugal.
2. School of Pharmacy, University of Coimbra, Coimbra, Portugal.
3. Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal.

Carlos Alves: PharmD. PhD candidate at School of Pharmacy, University of Coimbra, Coimbra, Portugal, and at CICS-UBI – Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal. Assistant Investigator at Centre for Health Technology Assessment and Drug Research (CHAD), AIBILI, Coimbra, Portugal; Ana F. Macedo: PharmD, PhD. Research Fellow at Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal; Francisco Batel-Marques: PharmD, PhD. Professor at School of Pharmacy, University of Coimbra, Coimbra, Portugal. Director of Centre for Health Technology Assessment and Drug Research (CHAD), AIBILI, Coimbra, Portugal

Correspondingauthor:

Carlos Miguel Costa Alves

Central Portugal Regional Pharmacovigilance Unit (UFC), Centre for Health Technology Assessment and Drug Research (CHAD)

AIBILI – Association for Innovation and Biomedical Research on Light and Image

Azinhaga de Santa Comba,Celas

3000-548 Coimbra, PORTUGAL

E-mail:

Telephone number: (+351) 239 480 100

Fax number: (+351) 239 480 117

Supplemental File 1 –References from studies presented at Table 1

w1.Diav-Citrin O, Shechtman S, Weinbaum D, et al (2008) Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J ClinPharmacol. 66(5): 695-705

w2.Eli Lilly and Company Clinical Trial Registry (2013) Results Observational/Non-interventional studies. Available at: Accessed 22 May 2013.

w3.Chambers CD, Johnson KA, Dick LM, et al (1996). Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 335(14):1010-5.

w4.Malm H, Klaukka T, Neuvonen PJ (2005). Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol. 106(6):1289-96.

w5.Källén BA, OtterbladOlausson P (2007). Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A ClinMolTeratol. 79(4):301-8.

w6.Alwan S, Reefhuis J, Rasmussen SA, et al (2007). Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 356(26):2684-92.

w7.Louik C, Lin AE, Werler MM, Hernández-Díaz S, Mitchell AA (2007). First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 356(26):2675-83.

w8.Oberlander TF, Warburton W, Misri S, et al (2008). Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B DevReprodToxicol. 83(1):68-76.

w9.Vestergaard P, Rejnmark L, Mosekilde L (2006) Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture.Calcif Tissue Int. 79(2):76-83.

w10.Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 296(24):2947-2953.

w11.Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD (2008) Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 179(4):319-326.

w12.Corley DA, Kubo A, Zhao W, Quesenberry C (2010) Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 139(1):93-101.

w13.Gray SL, LaCroix AZ, Larson J, et al (2010)Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women. Arch Intern Med. 170(9):765-771.

w14.Yu EW, Blackwell T, Ensrud KE, et al(2008) Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 83(4):251-259.

w15.Kaye JA, Jick H (2008) Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy28(8):951-959.

w16.Targownik LE, Lix LM, Leung S, Leslie WD (2010) Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 138(3):896-904.

w17.de Vries F, Cooper AL, Cockle SM, van Staa TP, Cooper C (2009) Fracture risk in patients receiving acidsuppressant medication alone and in combination with bisphosphonates. Osteoporos Int. 20(12):1989-1998.

w18.Roux C, Briot K, Gossec L, et al (2009) Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int. 84(1): 13-19.

w19.Kwok CS, Yeong JK, Loke YK (2011) Meta-analysis: risk of fractures with acid-suppressing medication. Bone.48(4):768-776.

w20.Eom CS, Park SM, Myung SK, Yun JM, Ahn JS (2011) Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med. 9(3):257-267.

w21.Pouwels S, Lalmohamed A, Souverein P, et al (2011). Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 22(3):903-10.

w22.Chiu HF, Huang YW, Chang CC, Yang CY (2010).Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf. 19(11):1131-6.

w23.Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC (2010) Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. The Lancet Oncology. 11(7):627-636.

w24.Bangalore S, Kumar S, Kjeldsen SE, et al (2011) Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomized trials. Lancet Oncol. 12(1):65-82.

w25.The ARB Trialists Collaboration (2011) Effects of telmisartan, irbesartan, valsartan, and candesartan, and losartan on cancers in 15 trials. J Hypertens. 29(4):623-635.

w26.Pasternak B, Svanström H, Callréus T, Melbye M, Hviid A (2011) Use of angiotensin receptor blockers and the risk of cancer. Circulation. 123(16):1729-1736.

w27.The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) Investigators (2008). Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 :1547–1559.

w28.The Telmisartan Randomized Assessment Study in ACEi Intolerant Subjects with Cardiovascular Disease (TRANSCEND) Investigators (2008). Effects of the angiotensin receptor blocker, telmisartan on cardiovascular events in high-risk patients intolerant to ACE-inhibitors: a randomized controlled trial. Lancet 372 :1174–1183

w29.Yusuf S, Diener H-C, Sacco RL, Cotton D, Ounpuu S, Lawton WA, et al., for the PRoFESS Study Group (2008). Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359:1225–1237.

w30.The Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Study Group (2010). Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1477–1490.

w31.Julius S, Kjeldsen E, Weber M, Brunner HR, Ekman S, Hansson L, et al (2004). Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the Valsartan Antihypertensive Long-term Use Evaluation trial (VALUE) randomized trial. Lancet 363:2022–2031.

w32.Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, et al (2003). Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362:759–766.

w33.Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al (2003). The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21:875–886.

w34.Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P (2001). The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870–78.

w35.Brenner BM, Cooper ME, de Zeeuw D, et al (2001). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–69.

w36.Berl T, Hunsicker LG, Lewis JB, et al (2003). Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 138:542–49.

w37.Dahlöf B, Devereux RB, Kjeldsen SE, et al, for the LIFE study group (2002). Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995–1003

w38.Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O (2003). Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 21:1563–74.

w39.Granger CB, McMurray JJV, Yusuf S, et al, for the CHARM Investigators and Committees (2003). Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:772–76

w40.Pfeffer MA, McMurray JJ, Velazquez EJ, et al (2003). Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893–906.

w41.Julius S, Nesbitt SD, Egan BM, et al (2006). Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354:1685–97.

w42.Mochizuki S, Dahlöf B, Shimizu M, et al, for the Jikei Heart Study group (2007). Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 369:1431–39.

w43.Zile MR, Gaasch WH, Anand IS, et al (2010). Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation 121:1393–405.

w44.Disertori M, Latini R, Barlera S, et al (2009). Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 360: 1606–17.

w45.Kasanuki H, Hagiwara N, Hosoda S, et al (2009). Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 30:1203–12.

w46.Sawada T, Yamada H, Dahlof B, Matsubara H (2009). Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 30: 2461–69.

w47.Cohn JN, Tognoni G (2001). A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667–75.

w48.The ACTIVE I Investigators (2011). Irbesartan in patients with atrial fibrillation. N Engl J Med. 364(10):928-38.

w49.Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving H-H, et al (2008). Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomized, placebo-controlled trials. Lancet 372:1394–1402.

w50.Sjolie AK, Klein R, Porta M, Orchard T, Parving H-H, Bilous R, et al (2008). Effect of candesartan on progression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomized placebo-controlled trial. Lancet 372:1385–1393.

w51.Dormandy JA, Charbonnel B, Eckland DJ, et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspectivepioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 366(9493):1279-1289.

w52.Lewis JD, Ferrara A, Peng T, et al (2011)Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 34(4):916-922.

w53.Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H (2012) Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. 55(7):1953-1962.

w54.Azoulay L, Yin H, Filion KB, et al (2012) The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 344:e3645 doi:10.1136/bmj.e3645.

w55.Parkin L, Sharples K, Hernandez RK, Jick SS (2011) Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ doi:10.1136/bmj.d2139

w56.Jick SS, Hernandez RK (2011) Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ. doi:10.1136/bmj.d2151.

w57.Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C (2009) Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. doi:10.1136/bmj.b2890.

w58.Van Hylckama V, Helmerhorst FM, Vandenbroucke JP, Doggen CJM, Rosendaal FR (2009) The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. doi:10.1136/bmj.b2921.

w59.Dinger JC, Heinemann LA, Kühl-Habich D (2007) The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 75(5):344-354.

w60.Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM (2007) Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. ObstetGynecol110(3):587-593.

w61.Dinger J, Assmann A, Möhner S, Minh TD (2010) Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J FamPlannReprod Health Care. 36(3):123-129.

w62.Ridker PM, Danielson E, Fonseca FA, et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 359(21):2195-2207.

w63.Shepherd J, Blauw GJ, Murphy MB et al (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomisedcontrolled trial. Lancet. 360(9346):1623-1630.

w64.Sattar N, Preiss D, Murray HM, et al (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 375(9716):735-742.

w65.Freeman DJ, Norrie J, Sattar N, et al (2001) Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study. Circulation. 103(3):357-362.

w66.Kostapanos MS, Liamis GL, Milionis HJ, Elisaf MS (2010) Do statins beneficially or adversely affect glucose homeostasis? CurrVascPharmacol. 8(5):612-631.

w67.Sabatine MS, Wiviott SD, Morrow DA, McCabe CH, Cannon CP (2004) High-dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy. Circulation. 110(suppl I):S834.

w68.Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM (2009) Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 32(10):1924-1929.

w69.Sukhija R, Prayaga S, Marashdeh M, et al (2009) Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med. 57(3):495-499.

w70.Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK (2010) Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am CollCardiol. 55(12):1209-1216.

w71.Thongtang N, Ai M, Otokozawa S, et al (2011) Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am J Cardiol.107(3):387-392.

w72.Mills EJ, Wu P, Chong G, et al (2011) Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 104(2):109-124.

w73.Culver AL, Ockene IS, Balasubramanian R, et al (2012) Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med. 172(2):144-152.

w74.Sever PS, Dahlof B, Poulter NR, et al (2003). Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet 361:1149-58.

w75.Collins R, Armitage J, Parish S, et al (2003). MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 361:2005-16.

w76.Freeman DJ, Norrie J, Sattar N, et al (2001). Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103:357-62.

w77.Keech A, Colquhoun D, Best J, et al (2003).Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose – results from LIPID trial. Diabetes Care 26:2713-21.

w78.Kjekshus J, Apetrei E, Barrios V, et al (2007). Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357:2248-61.

w79.Shepherd J, Blauw GJ, Murphy MB, et al (2002). Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 360:1623-30.

w80.Nakamura H, Arakawa K, Itakura H, et al (2006). Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial. Lancet 368:1155-63.

w81.Dwons JR, Clearfield M, Weis S, et al (1998). Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615-22.

w82.Scandinavian Simvastatin Survival Study study group (1994). Randomised trial of cholesterol lowering in 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-89.

w83.ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2002). Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288:2998-3007.

w84.GISSI PrevenzioneInvestigators (Gruppo Italiano per lo StudiodellaSopravvivenzanell’InfartoMiocardico) (2000). Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recente myocardial infarction: do stopped trials contribute to overall knowledge? Ital Heart J 1:810-20.

w85.Tavazzi L, maggioni AP, Marchioli R, et al (2008). Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 372:1231-39.

w86.Yokoi H, Nobuyoshi M, Mitsudo K, et al (2005). Three-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study. Circ J 69:875-83.

w87.The Pravastatin Multinational Study Group for Cardiac Risk Patients (1993). Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 72:1031-7.

w88.Al-Tureihi FIJ, Hassoun A, Wolf-Klein G, et al (2005) Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. J Am Med Dir Assoc. 6(2):105-108.

w89.Cunningham R, Dale B, Undy B, Isenberg H. (2003) Proton pump inhibitors as a risk factor for Clostridium difficilediarrhoea. J Hosp Infect. (54):243-245.

w90.Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D (2004) Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ. 171(1):33-38.

w91.Dial S, Delaney JAC, Barkun A, Suissa S (2005) Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 294(23):2989-2995.

w92.Muto C, Pokrywka M, Shutt K, et al (2005) A large outbreak of Clostridium difficile associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control HospEpidemiol. 26(3):273-280.

w93.Dial S, Delaney JA, Schneider V, Suissa S (2006) Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ. 175(7):745-748.

w94.Dial S, Kezouh A, Dascal A, et al (2008) Patterns of antibiotic use and risk of hospital admission for Clostridium difficile infection among elderly people in Quebec. CMAJ. 179(8):767-772.

w95.Akhtar AJ, Shaheen M (2007) Increasing incidence of Clostridium difficile-associated diarrhea in African-American and Hispanic patients: association with the use of proton pump inhibitor therapy. J Natl Med Assoc. 99(5):500-504.

w96.Aseeri M, Schroeder T, Kramer J, Zackula R (2008) Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol. 103(9):2308-2313.

w97.Cadle RM, Mansouri MD, Logan N, Kudva DR, Musher DM (2007)Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm. 64(22):2359-2363.

w98.Dalton BR, Lye-Maccannell T, Henderson EA, Maccannell DR, Louie TJ. (2009) Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting. Aliment PharmacolTher. 29(6):626-634.

w99.Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ (2007) Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis. 45(12):1543-1549.

w100.Howell MD, Novack V, Grgurich P, et al (2010) Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 170(9):784-790.

w101.Janarthanan S, Ditah I, Kutait A, et al (2010) A meta-analysis of 16 observational studies on proton pump inhibitor use and risk of Clostridium difficile associated diarrhea. Am J Gastroenterol 105(Suppl 1):S378

w102.Jayatilaka S, Shakov R, Eddi R, Bakaj G, Baddoura WJ, DeBari VA (2007) Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors. Ann Clin Lab Sci. 37(3):241-247.

w103.Kazakova SV, Ware K, Baughman B, et al (2006) A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med. 166(22):2518-2524.

w104.Kim JW, Lee KL, Jeong JB, et al (2010) Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea. World J Gastroenterol. 16(28):3573-3577.